• Citer

Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.

par Galmarini, Carlos M;Treilleux, I;Cardoso, Fatima ;Bernard, Chantal ;Durbecq, Virginie ;Gancberg, David ;Bissery, Marie Christine;Paesmans, Marianne ;Larsimont, Denis ;Piccart-Gebhart, Martine ;Di Leo, Angelo ;Dumontet, Charles
Référence Clinical cancer research, 14, 14, page (4511-4516)
Publication Publié, 2008-07

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Class III beta-tubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel.
Auteur:	Galmarini, Carlos M; Treilleux, I; Cardoso, Fatima; Bernard, Chantal; Durbecq, Virginie; Gancberg, David; Bissery, Marie Christine; Paesmans, Marianne; Larsimont, Denis; Piccart-Gebhart, Martine; Di Leo, Angelo; Dumontet, Charles
Informations sur la publication:	Clinical cancer research, 14, 14, page (4511-4516)
Statut de publication:	Publié, 2008-07
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Antineoplastic Agents -- therapeutic use
	Breast Neoplasms -- drug therapy
	Breast Neoplasms -- metabolism
	Doxorubicin -- therapeutic use
	Drug Resistance, Neoplasm -- physiology
	Female
	Humans
	Immunohistochemistry
	Middle Aged
	Protein Isoforms -- biosynthesis
	Taxoids -- therapeutic use
	Tubulin -- biosynthesis
	Tumor Markers, Biological -- analysis
Note générale:	Clinical Trial, Phase III
	Journal Article
	Multicenter Study
	Randomized Controlled Trial
Langue:	Anglais
Identificateurs:	urn:issn:1078-0432
	info:doi/10.1158/1078-0432.CCR-07-4741
	info:pii/14/14/4511
	info:scp/51649107171
	info:pmid/18628466